Abstracts tagged "quality of life"

Abstract Number: 059 • 2020 Pediatric Rheumatology Symposium
Challenges Faced by Families of Children with an Auto-inflammatory Disease
Lori Tucker¹, Maria Belen ², Jenny Tekano ², Iwona Niemietz ³, Martina Sundqvist ³ and Kelly Brown ³, ¹BC Children's Hospital, Vancouver, British Columbia, Canada, ²BC CHildren's Hospital, Vancouver, Canada, ³BC Children's Hospital Research Institute, Vancouver, Canada
Background/Purpose: Auto-inflammatory diseases (AIDs) are rare disorders that usually present in young children. Disease episodes, characterized by recurrent inflammation, are often frequent and unpredictable, and…
Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium
Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus
Lauren Ambler¹, Rula Issa ², Stephanie Pan ² and Rebecca Trachtman ², ¹Mount Sinai Hospital, New York, ²Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…
Abstract Number: 104 • 2020 Pediatric Rheumatology Symposium
Patients Perspectives on Living with a Systemic Autoinflammatory Disease: Impact on Quality of Life
Mariana Correia Marques¹, Nicole Tennermann ², Sivia Lapidus ³, Grant Schulert ⁴, Jennifer Tousseau ², Rashmi Sinha ⁵, Karen Durrant ⁶, Saskya Angevare ⁷ and Fatma Dedeoglu ⁸, ¹Boston Children's Hospital, Boston, Massachusetts, ², ³The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Maplewood, ⁴Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, ⁵Systemic JIA Foundation, Cincinnati, ⁶Autoinflammatory Alliance, San Francisco, ⁷Amersfoort, Netherlands, ⁸Boston Children's Hospital, Boston
Background/Purpose: Systemic autoinflammatory diseases (SAIDs) encompass multiple clinical entities in which spontaneous inflammation occurs due to dysregulation of the innate immune response. The variability in…
Abstract Number: 117 • 2020 Pediatric Rheumatology Symposium
Family Impact of Juvenile Localized Scleroderma
Katia Milovanova¹, Vimal Prajapati ², Merna Adly ², Rebeka Stevenson ³, Brendan Lethebe ² and Nadia Luca ², ¹University of Alberta, Edmonton, Alberta, Canada, ²University of Calgary, Calgary, Alberta, Canada, ³Cochrane, Alberta, Canada
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare autoimmune disease that can lead to significant morbidity. Previous studies have focused on predictors of patient health-related…
Abstract Number: 1120 • 2019 ACR/ARP Annual Meeting
Prevalence of Burnout in Rheumatology Professionals
Vivekanand Tiwari¹, Arthur Kavanaugh ², George Martin ³ and Martin Bergman ⁴, ¹Temple University, Philadelphia, PA, ²University of California, San Diego School of Medicine, La Jolla, CA, ³Dr. George Martin Dermatology Associates, Kihei, HI, ⁴Drexel University College of Medicine, Stockholm, Sweden
Background/Purpose: Burnout among physicians has major implications for health care. We measured prevalence of burnout in a large group of Rheumatology professionals attending a national…
Abstract Number: 1258 • 2019 ACR/ARP Annual Meeting
Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial
John Reveille¹, Atul Deodhar ², Diane Harrison ³, Elizabeth Hsia ⁴, Eric K H Chan ³, Shelly Kafka ⁵, Kim Hung Lo ³, Lilianne Kim ³ and Chenglong Han ³, ¹University of Texas McGovern Medical School, Houston, ²Oregon Health & Science University, Portland, OR, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: In patients with ankylosing spondylitis (AS), IV administration of the anti-TNFa antibody golimumab (GLM-IV) resulted in improvements in composite measures of various aspects of…
Abstract Number: 1466 • 2019 ACR/ARP Annual Meeting
Evaluation of Changes in Oral Health-Related Quality of Life over Time in Patients with Sjögren’s Syndrome
Naoto Azuma¹, Yoshinori Katada ², Aki Nishioka ³, Masahiro Sekiguchi ⁴, Masayasu Kitano ⁵, Sachie Kitano ¹, Hajime Sano ⁶ and Kiyoshi Matsui ¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Department of Rheumatology, Sakai City Medical Center, Sakai, Japan, ³Department of Rheumatology, Nishinomiya Watanabe Hospital, Nishinomiya, Japan, ⁴Departement of Rheumatology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan, ⁵Department of Rheumatology, Kyoto Okamoto Memorial Hospital, Kumiyama, Japan, ⁶Kyoto Okamoto Memorial Hospital, Kumiyama, Japan
Background/Purpose: In addition to xerostomia symptoms, patients with Sjögren’s syndrome (SS) experience pain and discomfort in the oral cavity, and difficulties in speaking and eating,…
Abstract Number: 1539 • 2019 ACR/ARP Annual Meeting
Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study
Laure Gossec¹, Stefan Siebert ², Paul Bergmans ³, Kurt De Vlam ⁴, Elisa Gremese ⁵, Beatriz Joven-Ibáñez ⁶, Ellie Korendowych ⁷, Tatiana Korotaeva ⁸, Wim Noël ⁹, Michael Nurmohamed ¹⁰, Christophe Richez ¹¹, Petros Sfikakis ¹², Pavel Smirnov ¹³, Elke Theander ¹⁴ and Josef Smolen ¹⁵, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Royal National Hospital for Rheumatic Diseases, Bath, Bath, United Kingdom, ⁸Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁹Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, ¹⁰Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, ¹¹Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ¹²Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹³Biostatistics and Medical Affairs, Janssen, Moscow, Russia, ¹⁴Biostatistics and Medical Affairs, Janssen, Solna, Sweden, ¹⁵Medical University of Vienna, Vienna, Austria
Background/Purpose: Psoriatic arthritis strongly impacts patients’ quality of life (QoL). Insights on the effects of biologic treatments on different domains of health-related QoL in a…
Abstract Number: 1545 • 2019 ACR/ARP Annual Meeting
Ixekizumab Significantly Improves Self-reported Overall Health as Measured by Short-Form-36 in Patients with Active Non-radiographic Axial Spondyloarthritis: 16- and 52-Week Results of a Phase 3 Randomized Trial (COAST-X)
Jessica Walsh¹, Marina Magrey ², Uta Kiltz ³, Xenofon Baraliakos ⁴, Maggie Weng ⁵, Theresa Hunter ⁶, Xiaoqi Li ⁶, Luis Leon ⁷, David Sandoval ⁷ and Kentaro Inui ⁸, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ³Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵National Cheng-Kung University Medical Center, Tainan, Taiwan (Republic of China), ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Department of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Previous studies have determined that axial spondyloarthritis (axSpA) significantly impairs patients’ health-related quality of life (HRQoL).1 The patients with nr-axSpA have the same disease…
Abstract Number: 1844 • 2019 ACR/ARP Annual Meeting
The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE
Alexandra Watts¹, Desiree Azizoddin ², Shadi Gholizadeh ³, Sarah Mills ⁴, Geraldine Zamora ⁵, Daniel Wallace ⁶, Meenakshi Jolly ⁷, Michael Weisman ⁸ and Perry Nicassio ⁹, ¹University of California, Los Angeles, Los Angeles, CA, ²Dana-Farber Cancer Institute, Boston, MA, ³McGill University, Montreal, Canada, ⁴Lineberger Comprehensive Cancer Center, Chapel Hill, NC, ⁵Manila Doctors Hospital, Manila, Philippines, ⁶Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁷Rush University Medical Center, Chicago, IL, ⁸David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: It is well known that patients with SLE are often afflicted with deficits in quality of life and problems with physical impairment and psychosocial…
Abstract Number: 1897 • 2019 ACR/ARP Annual Meeting
Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story
Martín Valdez-López¹, Jonathan Campos-Guzmán ¹, Ana Barrera-Vargas ², Samuel Govea-Peláez ¹, Diana Gómez-Martín ¹, Jorge Alcocer-Varela ¹, Eduardo Aguirre-Aguilar ¹, Diana Padilla-Ortíz ³ and Javier Merayo-Chalico ¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Universidad De La Sabana, Bogotá, Cundinamarca, Colombia
Background/Purpose: Although SLE is uncommon in men, the disease is usually more severe and requires more aggressive immunosuppression in male patients. There are multiple studies…
Abstract Number: 2262 • 2019 ACR/ARP Annual Meeting
Evaluation of Illness Perception in Systemic Sclerosis Patients with Pulmonary Involvement
Bruna Giusto Bunjes¹, Percival Degrava Sampaio-Barros ² and Ana Paula Luppino-Assad ³, ¹1- Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil., Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Brazil, Sao Paulo, Brazil, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil., Sao Paulo, Brazil
Background/Purpose: Lung disease is the current leading cause of death and the most common severe complication of systemic sclerosis (SSc), causing a significant adverse impact in quality of…
Abstract Number: 2526 • 2019 ACR/ARP Annual Meeting
Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus
Ioannis Parodis¹, Sofia Soukka ¹, Alvaro Gomez ¹, Yvonne Enman ¹, Petter Johansson ¹, Sharzad Emamikia ¹ and Katerina Chatzidionysiou ¹, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffer an impaired health-related quality of life (HRQoL), and the majority of them experience fatigue as a major…
Abstract Number: 2702 • 2019 ACR/ARP Annual Meeting
Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group
Alessandra Alongi¹, Serana Calandra ¹, Susan Thornhill ², Jennifer Stinson ³, Jen Horonjeff ⁴, Daniel Horton ⁵, Alessandro Consolaro ⁶ and Esi Morgan ⁷, ¹Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, ²Thornhill Associates, Hermosa Beach, USA, Hermosa Beach, ³The Hospital for Sick Children, and University of Toronto, Toronto, Canada, Toronto, ⁴Columbia University Medical Center, New York, USA, New York, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health Sciences, New Brunswick, ⁶Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, ⁷Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH
Background/Purpose: The OMERACT Juvenile Idiopathic Arthritis Core Set Working Group formed in 2015 as an international initiative to revise the existing Core Set with relevant…
Abstract Number: 2765 • 2019 ACR/ARP Annual Meeting
Assessing the Impact of Digital Health Coaching on Quality Adjusted Life Years, Symptom Severity and Disease Activity in Patients with Rheumatoid Arthritis
Matt Allsion¹, Michael McMorris ², Dhiren Patel ² and B Stephen Burton ³, ¹Pack Health, Birmigham, AL, ²Pack Health, Birmingham, ³Pack Health, Birmingham, AL
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. RA has a significant negative impact on the ability to perform daily…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.